Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Par Pharmaceutical

AstraZeneca AZ

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

Will receive $250m upfront with a further $1.27bn if drug reaches market in two indications

- PMLiVE

How merging firms can manage culture change

Addressing the potential problems and finding the solutions

- PMLiVE

Pfizer decides against long-discussed break-up

Says dividing its R&D and generics businesses would disrupt rather than create value

- PMLiVE

Lundbeck challenge to EC pay-for-delay ruling fails

Court upholds €94m fine for paying off firms to delay launch of Celexa generics

- PMLiVE

Nestlé Health Science buys medical device firm

Acquisition of UK's Phagenesis expected to be completed by 2019

- PMLiVE

Teva acquires Allergan’s generics operations in $38.8bn deal

Also discloses $500m agreement to purchase the Irish firm’s distribution business

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

EMA suspends generic drugs on data integrity concerns

Reports by FDA and WHO find evidence of data manipulation by Semler Research Centre

- PMLiVE

Recordati snaps up Swiss pharma company Pro Farma

Follows group's recent acquisition of Italian firm Italchimici

- PMLiVE

Juno cleared to restart CAR-T trial after deaths

Study attributes fatalities to pre-conditioning therapy, not the cancer immunotherapy

Bristol-Myers Squibb (BMS) building

Bristol-Myers Squibb acquires Cormorant for $520m

Deal with Swedish firm will boost BMS' oncology pipeline

- PMLiVE

Pfizer set to snap up Bind’s assets for $20m

Biotech approves 'stalking horse' bid from the pharma giant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links